Tag Archives: Prof. Özlem Türeci

BioNTech and DualityBio Initiate Phase 3 Trial for HER2-Targeting ADC in Metastatic Breast Cancer

(IN BRIEF) BioNTech and Duality Biologics have announced the commencement of a pivotal Phase 3 trial for BNT323/DB-1303, a next-generation antibody-drug conjugate (ADC) targeting the Human Epidermal Growth Factor Receptor 2 (HER2) in metastatic breast cancer. The trial will enroll … Read the full press release

BioNTech to Showcase Advances in Cancer Therapy at ESMO Congress 2023

(IN BRIEF) BioNTech will be presenting updates on multiple programs across its oncology pipeline at the European Society for Molecular Oncology (ESMO) Congress 2023. These updates include data on investigational CAR-T and ex-vivo T cell therapies, a novel ADC (antibody-drug … Read the full press release